OKYO Pharma Enrolls First Patients in Phase 3 Trial for Neuropathic Corneal Pain

OKYO Pharma Limited has announced the enrollment of the first patients in a Phase 3 pivotal trial for its investigational therapy, Urcosimod, aimed at treating neuropathic corneal pain.